Concepts (253)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 27 | 2026 | 430 | 6.520 |
Why?
|
| Tuberculosis | 27 | 2026 | 550 | 5.930 |
Why?
|
| Tuberculosis, Pulmonary | 13 | 2026 | 238 | 3.590 |
Why?
|
| DNA Methylation | 5 | 2025 | 1077 | 1.750 |
Why?
|
| Immune Tolerance | 4 | 2024 | 151 | 1.700 |
Why?
|
| Feces | 6 | 2025 | 721 | 1.440 |
Why?
|
| Molecular Diagnostic Techniques | 5 | 2024 | 166 | 1.290 |
Why?
|
| Epigenesis, Genetic | 6 | 2026 | 757 | 1.260 |
Why?
|
| Adaptive Immunity | 3 | 2021 | 101 | 1.210 |
Why?
|
| Sputum | 9 | 2025 | 113 | 1.180 |
Why?
|
| BCG Vaccine | 5 | 2023 | 105 | 1.080 |
Why?
|
| Interferon-gamma Release Tests | 5 | 2026 | 91 | 1.020 |
Why?
|
| Antitubercular Agents | 10 | 2026 | 275 | 1.000 |
Why?
|
| HIV Infections | 13 | 2025 | 2049 | 0.960 |
Why?
|
| Real-Time Polymerase Chain Reaction | 4 | 2025 | 526 | 0.870 |
Why?
|
| Citric Acid Cycle | 1 | 2024 | 43 | 0.850 |
Why?
|
| Lipopolysaccharides | 2 | 2025 | 299 | 0.810 |
Why?
|
| Mycobacterium bovis | 1 | 2022 | 29 | 0.750 |
Why?
|
| Sensitivity and Specificity | 15 | 2025 | 2085 | 0.740 |
Why?
|
| Fetal Blood | 1 | 2023 | 176 | 0.730 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2021 | 124 | 0.600 |
Why?
|
| Bacteriological Techniques | 2 | 2016 | 88 | 0.580 |
Why?
|
| Communicable Diseases | 1 | 2021 | 155 | 0.580 |
Why?
|
| Leukocytes | 1 | 2020 | 205 | 0.580 |
Why?
|
| Th1 Cells | 2 | 2026 | 158 | 0.570 |
Why?
|
| Ascaris lumbricoides | 1 | 2018 | 19 | 0.550 |
Why?
|
| Schistosoma haematobium | 1 | 2018 | 16 | 0.550 |
Why?
|
| Schistosomiasis | 1 | 2018 | 51 | 0.530 |
Why?
|
| Immunity, Innate | 2 | 2021 | 406 | 0.520 |
Why?
|
| Ascariasis | 1 | 2018 | 76 | 0.510 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2017 | 500 | 0.500 |
Why?
|
| Humans | 58 | 2026 | 131163 | 0.490 |
Why?
|
| Transcriptome | 2 | 2022 | 1103 | 0.480 |
Why?
|
| Schistosoma | 1 | 2016 | 13 | 0.480 |
Why?
|
| Immunologic Factors | 2 | 2021 | 190 | 0.460 |
Why?
|
| Antigens, Helminth | 1 | 2016 | 187 | 0.440 |
Why?
|
| Population Surveillance | 2 | 2022 | 396 | 0.430 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 2 | 2025 | 86 | 0.370 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2323 | 0.360 |
Why?
|
| Macrophages | 1 | 2016 | 667 | 0.350 |
Why?
|
| Signal Transduction | 2 | 2021 | 4686 | 0.330 |
Why?
|
| T-Lymphocytes | 3 | 2025 | 1722 | 0.330 |
Why?
|
| Skin | 3 | 2026 | 545 | 0.320 |
Why?
|
| Immunologic Memory | 2 | 2021 | 195 | 0.300 |
Why?
|
| Antigens, Bacterial | 2 | 2025 | 319 | 0.300 |
Why?
|
| Child | 17 | 2025 | 26341 | 0.290 |
Why?
|
| Biomarkers | 4 | 2026 | 3385 | 0.270 |
Why?
|
| Cytokines | 4 | 2026 | 1339 | 0.260 |
Why?
|
| Interferon-gamma | 3 | 2025 | 544 | 0.260 |
Why?
|
| Animals | 10 | 2026 | 33912 | 0.260 |
Why?
|
| DNA, Bacterial | 3 | 2024 | 481 | 0.260 |
Why?
|
| Interleukin-4 | 2 | 2018 | 144 | 0.250 |
Why?
|
| Adult | 18 | 2026 | 31282 | 0.240 |
Why?
|
| South Africa | 2 | 2023 | 98 | 0.240 |
Why?
|
| Child, Preschool | 9 | 2025 | 15110 | 0.230 |
Why?
|
| Carotenoids | 1 | 2026 | 79 | 0.220 |
Why?
|
| B7-H1 Antigen | 1 | 2026 | 136 | 0.220 |
Why?
|
| Succinic Acid | 1 | 2024 | 13 | 0.220 |
Why?
|
| Succinates | 1 | 2024 | 14 | 0.220 |
Why?
|
| Adolescent | 12 | 2025 | 20987 | 0.220 |
Why?
|
| Fruit | 1 | 2026 | 227 | 0.220 |
Why?
|
| Inflammation | 2 | 2022 | 1489 | 0.210 |
Why?
|
| Everolimus | 1 | 2024 | 50 | 0.210 |
Why?
|
| Prospective Studies | 9 | 2026 | 6459 | 0.210 |
Why?
|
| Gene Silencing | 1 | 2025 | 229 | 0.210 |
Why?
|
| Vegetables | 1 | 2026 | 267 | 0.210 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2025 | 889 | 0.200 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2018 | 401 | 0.200 |
Why?
|
| Host-Pathogen Interactions | 2 | 2026 | 254 | 0.200 |
Why?
|
| Metabolome | 1 | 2026 | 326 | 0.200 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2025 | 156 | 0.190 |
Why?
|
| Young Adult | 6 | 2025 | 10103 | 0.190 |
Why?
|
| Immunity | 1 | 2023 | 178 | 0.190 |
Why?
|
| Ultraviolet Therapy | 1 | 2022 | 2 | 0.190 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2022 | 22 | 0.180 |
Why?
|
| Guinea Pigs | 1 | 2022 | 147 | 0.180 |
Why?
|
| Isosporiasis | 1 | 2021 | 3 | 0.180 |
Why?
|
| Immunocompromised Host | 2 | 2021 | 315 | 0.180 |
Why?
|
| CRISPR-Cas Systems | 1 | 2025 | 317 | 0.180 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 57 | 0.170 |
Why?
|
| Sexual and Gender Minorities | 1 | 2022 | 67 | 0.170 |
Why?
|
| Cryptococcus | 1 | 2021 | 2 | 0.170 |
Why?
|
| Herpesvirus 8, Human | 1 | 2021 | 48 | 0.170 |
Why?
|
| Systems Biology | 1 | 2021 | 60 | 0.170 |
Why?
|
| Cryptococcosis | 1 | 2021 | 37 | 0.160 |
Why?
|
| Kava | 1 | 2020 | 8 | 0.160 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 67 | 0.160 |
Why?
|
| Allergy and Immunology | 1 | 2021 | 30 | 0.160 |
Why?
|
| History, 19th Century | 1 | 2021 | 109 | 0.160 |
Why?
|
| Vaccination | 2 | 2023 | 1060 | 0.160 |
Why?
|
| Male | 18 | 2026 | 64957 | 0.160 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2021 | 121 | 0.160 |
Why?
|
| Mozambique | 3 | 2025 | 21 | 0.160 |
Why?
|
| Coinfection | 2 | 2025 | 187 | 0.160 |
Why?
|
| Eosinophilia | 1 | 2021 | 112 | 0.160 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2021 | 272 | 0.160 |
Why?
|
| Lung | 2 | 2026 | 1535 | 0.160 |
Why?
|
| Sarcoma, Kaposi | 1 | 2021 | 129 | 0.160 |
Why?
|
| Transcription Factors | 2 | 2021 | 2406 | 0.160 |
Why?
|
| Cellular Senescence | 1 | 2022 | 217 | 0.150 |
Why?
|
| Urologic Neoplasms | 1 | 2020 | 30 | 0.150 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 226 | 0.150 |
Why?
|
| Diarrhea | 1 | 2021 | 301 | 0.150 |
Why?
|
| Case-Control Studies | 2 | 2025 | 3359 | 0.150 |
Why?
|
| Herpesviridae Infections | 1 | 2021 | 148 | 0.150 |
Why?
|
| Flow Cytometry | 2 | 2026 | 765 | 0.150 |
Why?
|
| Female | 17 | 2026 | 70963 | 0.150 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 78 | 0.150 |
Why?
|
| Diet | 1 | 2026 | 1121 | 0.150 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2021 | 239 | 0.150 |
Why?
|
| Anti-HIV Agents | 1 | 2023 | 345 | 0.150 |
Why?
|
| History, 20th Century | 1 | 2021 | 365 | 0.150 |
Why?
|
| Adjuvants, Immunologic | 1 | 2021 | 393 | 0.150 |
Why?
|
| RNA | 1 | 2022 | 517 | 0.150 |
Why?
|
| Gene Expression | 1 | 2023 | 1481 | 0.140 |
Why?
|
| Immunization | 1 | 2020 | 269 | 0.140 |
Why?
|
| Health Personnel | 1 | 2023 | 541 | 0.140 |
Why?
|
| Uganda | 3 | 2025 | 85 | 0.140 |
Why?
|
| Receptors, Cytokine | 1 | 2018 | 65 | 0.140 |
Why?
|
| Colony Count, Microbial | 1 | 2018 | 86 | 0.140 |
Why?
|
| Limit of Detection | 1 | 2018 | 74 | 0.140 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2018 | 38 | 0.130 |
Why?
|
| Mycobacterium chelonae | 1 | 2017 | 4 | 0.130 |
Why?
|
| Autoantibodies | 1 | 2021 | 451 | 0.130 |
Why?
|
| Wound Healing | 1 | 2021 | 490 | 0.130 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2017 | 46 | 0.130 |
Why?
|
| Viral Vaccines | 1 | 2020 | 324 | 0.130 |
Why?
|
| Precision Medicine | 1 | 2020 | 388 | 0.120 |
Why?
|
| Betacoronavirus | 1 | 2020 | 275 | 0.120 |
Why?
|
| Age Factors | 1 | 2023 | 2825 | 0.120 |
Why?
|
| Tanzania | 3 | 2024 | 68 | 0.120 |
Why?
|
| Helminths | 1 | 2017 | 53 | 0.120 |
Why?
|
| Calibration | 1 | 2016 | 92 | 0.120 |
Why?
|
| CD56 Antigen | 1 | 2016 | 26 | 0.120 |
Why?
|
| Phagosomes | 1 | 2016 | 38 | 0.120 |
Why?
|
| Risk Factors | 3 | 2026 | 11074 | 0.120 |
Why?
|
| Hookworm Infections | 1 | 2017 | 127 | 0.120 |
Why?
|
| Dermoscopy | 1 | 2015 | 2 | 0.120 |
Why?
|
| Reference Standards | 1 | 2016 | 231 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2021 | 768 | 0.120 |
Why?
|
| CD3 Complex | 1 | 2016 | 96 | 0.110 |
Why?
|
| Intravital Microscopy | 1 | 2015 | 20 | 0.110 |
Why?
|
| Immunophenotyping | 1 | 2016 | 332 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 339 | 0.110 |
Why?
|
| Middle Aged | 9 | 2026 | 28601 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 351 | 0.110 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 2904 | 0.110 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 214 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2021 | 5063 | 0.110 |
Why?
|
| Age of Onset | 1 | 2016 | 592 | 0.110 |
Why?
|
| Latent Tuberculosis | 1 | 2016 | 75 | 0.110 |
Why?
|
| Interleukin-10 | 1 | 2016 | 192 | 0.110 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 354 | 0.110 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 109 | 0.110 |
Why?
|
| Obesity | 1 | 2026 | 2426 | 0.110 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 335 | 0.100 |
Why?
|
| Lysosomes | 1 | 2016 | 268 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 712 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 463 | 0.100 |
Why?
|
| Africa South of the Sahara | 2 | 2025 | 121 | 0.090 |
Why?
|
| Pandemics | 1 | 2020 | 1118 | 0.090 |
Why?
|
| Prognosis | 2 | 2026 | 4886 | 0.090 |
Why?
|
| Cells, Cultured | 1 | 2018 | 2885 | 0.090 |
Why?
|
| Pathology, Molecular | 2 | 2022 | 61 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2025 | 227 | 0.080 |
Why?
|
| Infant | 6 | 2025 | 13352 | 0.080 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2465 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 2304 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 4697 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 1826 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 909 | 0.070 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2007 | 18 | 0.070 |
Why?
|
| Mice | 1 | 2024 | 18301 | 0.060 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2007 | 51 | 0.060 |
Why?
|
| Fruit and Vegetable Juices | 1 | 2026 | 7 | 0.060 |
Why?
|
| Time Factors | 1 | 2016 | 6196 | 0.060 |
Why?
|
| Indonesia | 1 | 2026 | 21 | 0.060 |
Why?
|
| Geriatric Psychiatry | 1 | 2006 | 12 | 0.060 |
Why?
|
| beta Carotene | 1 | 2026 | 37 | 0.060 |
Why?
|
| Foreign Medical Graduates | 1 | 2006 | 10 | 0.060 |
Why?
|
| Aged | 2 | 2023 | 21025 | 0.060 |
Why?
|
| Alaska | 1 | 2025 | 10 | 0.060 |
Why?
|
| Proline | 1 | 2026 | 80 | 0.060 |
Why?
|
| Phenotype | 2 | 2026 | 4497 | 0.060 |
Why?
|
| Family Practice | 1 | 2006 | 84 | 0.060 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2025 | 19 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 2596 | 0.060 |
Why?
|
| Macrophages, Alveolar | 1 | 2025 | 52 | 0.050 |
Why?
|
| Jurkat Cells | 1 | 2025 | 83 | 0.050 |
Why?
|
| Tuberculin Test | 1 | 2025 | 120 | 0.050 |
Why?
|
| Neutrophils | 1 | 2026 | 371 | 0.050 |
Why?
|
| HIV-1 | 1 | 2007 | 490 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2025 | 362 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 294 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2025 | 633 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 1882 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2022 | 58 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2025 | 859 | 0.050 |
Why?
|
| HEK293 Cells | 1 | 2025 | 801 | 0.050 |
Why?
|
| Kenya | 1 | 2022 | 60 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2006 | 460 | 0.050 |
Why?
|
| Phototherapy | 1 | 2022 | 37 | 0.040 |
Why?
|
| Isospora | 1 | 2021 | 3 | 0.040 |
Why?
|
| Gene Editing | 1 | 2025 | 238 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2017 | 256 | 0.040 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2021 | 45 | 0.040 |
Why?
|
| HIV | 1 | 2023 | 174 | 0.040 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2022 | 78 | 0.040 |
Why?
|
| Anti-Retroviral Agents | 1 | 2023 | 155 | 0.040 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2021 | 18 | 0.040 |
Why?
|
| Invasive Fungal Infections | 1 | 2021 | 22 | 0.040 |
Why?
|
| Isoniazid | 1 | 2021 | 69 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2022 | 12936 | 0.040 |
Why?
|
| Minority Groups | 1 | 2022 | 260 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2021 | 195 | 0.040 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2021 | 134 | 0.040 |
Why?
|
| Cell Line | 1 | 2025 | 2552 | 0.040 |
Why?
|
| Rituximab | 1 | 2021 | 170 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2026 | 1717 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2021 | 288 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2006 | 775 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 1129 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 365 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 266 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 1410 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 208 | 0.040 |
Why?
|
| United States | 3 | 2022 | 12072 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2021 | 308 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2019 | 93 | 0.030 |
Why?
|
| Syndrome | 1 | 2021 | 1155 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 1173 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2026 | 2833 | 0.030 |
Why?
|
| Metabolomics | 1 | 2021 | 501 | 0.030 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2017 | 52 | 0.030 |
Why?
|
| DNA | 1 | 2022 | 1399 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2017 | 123 | 0.030 |
Why?
|
| Photometry | 1 | 2015 | 4 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2006 | 1223 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2021 | 807 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 688 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2017 | 298 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2026 | 3436 | 0.030 |
Why?
|
| Rural Population | 1 | 2017 | 276 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 1239 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1928 | 0.020 |
Why?
|
| Genomics | 1 | 2021 | 1621 | 0.020 |
Why?
|
| Mutation | 1 | 2025 | 6099 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2023 | 17753 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2006 | 184 | 0.010 |
Why?
|
| Data Collection | 1 | 2006 | 370 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2017 | 8635 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2006 | 1050 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 4066 | 0.010 |
Why?
|